Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836824 | 0.93 | MCHR1 (0.69) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL3831494 | 0.92 | MCHR1 (0.65) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL3833554 | 0.88 | MCHR1 (0.68) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL4481409 | 0.85 | MCHR1 (0.69) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL13818032 | 0.82 | MCHR1 (0.54) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL13818030 | 0.82 | MCHR1 (0.57) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL13824423 | 0.82 | MCHR1 (0.57) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL3834936 | 0.81 | MCHR1 (0.72) | MCHR1ADRA1DADRA1AADRA1BHTR2B | |
| SCHEMBL3831822 | 0.80 | MCHR1 (0.73) | MCHR1 | |
| SCHEMBL13818055 | 0.80 | MCHR1 (0.70) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553089-B1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMA CO LTD (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1553089-A1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | MC1R, MCHR1, MCHR2 | MCHR1 2/4885ADRA1D 19/4885ADRA1A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.